<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00743145</url>
  </required_header>
  <id_info>
    <org_study_id>IRB# 5693</org_study_id>
    <secondary_id>DA19239</secondary_id>
    <nct_id>NCT00743145</nct_id>
  </id_info>
  <brief_title>Effects of Low-dose Naltrexone in Combination With a Range of Smoked Marijuana</brief_title>
  <official_title>Effects of Low-dose Naltrexone in Combination With a Range of Smoked Marijuana</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Research Foundation for Mental Hygiene, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In heavy marijuana smokers, opioid receptor blockade increases the subjective and
      cardiovascular effects of marijuana. The current study was designed to clarify
      opioid-cannabinoid interactions by assessing how naltrexone shifts the dose-response function
      for marijuana-elicited effects in heavy marijuana smokers. For this within-subject,
      double-blind study, a marijuana smoking procedure was designed to characterize a
      dose-response relationship for marijuana's subjective and cardiovascular effects under
      blinded conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double-blind, placebo-controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective Marijuana Effects</measure>
    <time_frame>180 minutes after marijuana administration, during each of 8 outpatient sessions over the course of 3-6 weeks.</time_frame>
    <description>Subjective ratings of marijuana's quality and effect ('Strength', 'Good Effect', 'High', 'Stimulation') and craving ('Want Marijuana') as a function of active puffs and naltrexone, using a visual analogue scale with a series of 100 mm long lines labeled 'not at all' at one end (0 mm) and 'extremely' at the other end (100 mm). Participants were instructed to indicate how they felt at that particular moment. Higher ratings indicate more agreement with the statement.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Marijuana Smoking</condition>
  <arm_group>
    <arm_group_label>Placebo naltrexone + Inactive marijuana</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo naltrexone capsules (0mg), inactive marijuana (0% THC). Each study participant underwent 8 conditions in a randomized order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo naltrexone + Active marijuana (5.5% THC)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo naltrexone capsules (0mg), active marijuana (5.5% THC). Each study participant underwent 8 conditions in a randomized order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo naltrexone + Active marijuana (6.2% THC)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo naltrexone capsules (0mg), active marijuana (6.2% THC). Each study participant underwent 8 conditions in a randomized order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naltrexone + Active marijuana (5.5% THC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naltrexone capsules (12mg), active marijuana (5.5% THC). Each study participant underwent 8 conditions in a randomized order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naltrexone + Active marijuana (6.2% THC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naltrexone capsules (0mg), active marijuana (6.2% THC). Each study participant underwent 8 conditions in a randomized order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naltrexone + Inactive marijuana</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Naltrexone capsules (12mg), inactive marijuana (0% THC). Each study participant underwent 8 conditions in a randomized order.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inactive Marijuana (0% THC)</intervention_name>
    <description>Marijuana cigarette containing 0% THC</description>
    <arm_group_label>Naltrexone + Inactive marijuana</arm_group_label>
    <arm_group_label>Placebo naltrexone + Inactive marijuana</arm_group_label>
    <other_name>Cannabis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Marijuana (5.5% THC)</intervention_name>
    <description>Marijuana cigarette containing 5.5% THC</description>
    <arm_group_label>Naltrexone + Active marijuana (5.5% THC)</arm_group_label>
    <arm_group_label>Placebo naltrexone + Active marijuana (5.5% THC)</arm_group_label>
    <other_name>Cannabis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Marijuana (6.2% THC)</intervention_name>
    <description>Marijuana cigarette containing 6.2% THC</description>
    <arm_group_label>Naltrexone + Active marijuana (6.2% THC)</arm_group_label>
    <arm_group_label>Placebo naltrexone + Active marijuana (6.2% THC)</arm_group_label>
    <other_name>Cannabis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>Naltrexone (12mg/70kg)</description>
    <arm_group_label>Naltrexone + Active marijuana (5.5% THC)</arm_group_label>
    <arm_group_label>Naltrexone + Active marijuana (6.2% THC)</arm_group_label>
    <arm_group_label>Naltrexone + Inactive marijuana</arm_group_label>
    <other_name>Revia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo naltrexone</intervention_name>
    <description>Naltrexone (0mg)</description>
    <arm_group_label>Placebo naltrexone + Active marijuana (5.5% THC)</arm_group_label>
    <arm_group_label>Placebo naltrexone + Active marijuana (6.2% THC)</arm_group_label>
    <arm_group_label>Placebo naltrexone + Inactive marijuana</arm_group_label>
    <other_name>PBO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current marijuana use

          -  Able to perform study procedures

          -  Women practicing an effective form of birth control

        Exclusion Criteria:

          -  Current repeated illicit drug use (other than marijuana)

          -  Presence of significant medical illness (e.g., diabetes, cardiovascular
             disease,hypertension, hepatitis, clinically significant laboratory abnormalities, LFTs
             &gt; 3x upper limit of normal, blood pressure &gt; 140/90
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret Haney, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 26, 2008</study_first_submitted>
  <study_first_submitted_qc>August 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2008</study_first_posted>
  <results_first_submitted>August 14, 2017</results_first_submitted>
  <results_first_submitted_qc>August 16, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 14, 2018</results_first_posted>
  <last_update_submitted>August 16, 2018</last_update_submitted>
  <last_update_submitted_qc>August 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>Margaret Haney</investigator_full_name>
    <investigator_title>Clinical Psychaitrist</investigator_title>
  </responsible_party>
  <keyword>naltrexone</keyword>
  <keyword>smoked marijuana</keyword>
  <keyword>marijuana use</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
    <mesh_term>Marijuana Use</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo, Naltrexone, Marijuana</title>
          <description>A total of 23 participants enrolled but only 19 completed. All patients participated in all conditions; they were randomized to placebo or naltrexone treatment in a counterbalanced fashion, and underwent all smoking conditions in separate, counterbalanced sessions.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>19 participants completed the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo, Naltrexone, Marijuana</title>
          <description>During each of the 8 outpatient sessions, participants smoked a total of 6 puffs from 3 marijuana cigarettes (2 puffs from each cigarette). Marijuana administration occurred 45 minutes after capsule administration. The number of active versus inactive cigarettes smoked during each session varied, according to active puff conditions (i.e., 0 puffs = 3 inactive cigarettes; 2 puffs = 1 active + 2 inactive cigarette; 4 puffs = 2 active + 1 inactive cigarette; 6 puffs = 3 active + 0 inactive cigarette). Cigarettes were color coded, indicating the order in which they were to be smoked and active cigarettes were always smoked before inactive. A within-subject design was used in which all participants were exposed to each of the puff conditions in combination with naltrexone or placebo. The order of naltrexone dosing and puff condition was randomized within the session and across participants.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.0" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subjective Marijuana Effects</title>
        <description>Subjective ratings of marijuana's quality and effect ('Strength', 'Good Effect', 'High', 'Stimulation') and craving ('Want Marijuana') as a function of active puffs and naltrexone, using a visual analogue scale with a series of 100 mm long lines labeled 'not at all' at one end (0 mm) and 'extremely' at the other end (100 mm). Participants were instructed to indicate how they felt at that particular moment. Higher ratings indicate more agreement with the statement.</description>
        <time_frame>180 minutes after marijuana administration, during each of 8 outpatient sessions over the course of 3-6 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Naltrexone + Inactive Marijuana</title>
            <description>Placebo naltrexone capsules (0mg), inactive marijuana (0% THC). Each study participant underwent 8 conditions in a randomized order.
Inactive Marijuana (0% THC): Marijuana cigarette containing 0% THC
Placebo naltrexone: Naltrexone (0mg)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Naltrexone + Active Marijuana (5.5% THC)</title>
            <description>Placebo naltrexone capsules (0mg), active marijuana (5.5% THC). Each study participant underwent 8 conditions in a randomized order.
Active Marijuana (5.5% THC): Marijuana cigarette containing 5.5% THC
Placebo naltrexone: Naltrexone (0mg)</description>
          </group>
          <group group_id="O3">
            <title>Placebo Naltrexone + Active Marijuana (6.2% THC)</title>
            <description>Placebo naltrexone capsules (0mg), active marijuana (6.2% THC). Each study participant underwent 8 conditions in a randomized order.
Active Marijuana (6.2% THC): Marijuana cigarette containing 6.2% THC
Placebo naltrexone: Naltrexone (0mg)</description>
          </group>
          <group group_id="O4">
            <title>Naltrexone + Active Marijuana (5.5% THC)</title>
            <description>Naltrexone capsules (12mg), active marijuana (5.5% THC). Each study participant underwent 8 conditions in a randomized order.
Active Marijuana (5.5% THC): Marijuana cigarette containing 5.5% THC
Naltrexone: Naltrexone (12mg/70kg)</description>
          </group>
          <group group_id="O5">
            <title>Naltrexone + Active Marijuana (6.2% THC)</title>
            <description>Naltrexone capsules (0mg), active marijuana (6.2% THC). Each study participant underwent 8 conditions in a randomized order.
Active Marijuana (6.2% THC): Marijuana cigarette containing 6.2% THC
Naltrexone: Naltrexone (12mg/70kg)</description>
          </group>
          <group group_id="O6">
            <title>Naltrexone + Inactive Marijuana</title>
            <description>Naltrexone capsules (12mg), inactive marijuana (0% THC). Each study participant underwent 8 conditions in a randomized order.
Inactive Marijuana (0% THC): Marijuana cigarette containing 0% THC
Naltrexone: Naltrexone (12mg/70kg)</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Marijuana Effects</title>
          <description>Subjective ratings of marijuana's quality and effect ('Strength', 'Good Effect', 'High', 'Stimulation') and craving ('Want Marijuana') as a function of active puffs and naltrexone, using a visual analogue scale with a series of 100 mm long lines labeled 'not at all' at one end (0 mm) and 'extremely' at the other end (100 mm). Participants were instructed to indicate how they felt at that particular moment. Higher ratings indicate more agreement with the statement.</description>
          <units>units on a scale (0-100mm)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="19"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&quot;Marijuana Strength&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" spread="1"/>
                    <measurement group_id="O2" value="15" spread="1"/>
                    <measurement group_id="O3" value="16" spread="2"/>
                    <measurement group_id="O4" value="16" spread="2"/>
                    <measurement group_id="O5" value="20" spread="2"/>
                    <measurement group_id="O6" value="16" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&quot;Marijuana Good Effect&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" spread="2"/>
                    <measurement group_id="O2" value="37" spread="3"/>
                    <measurement group_id="O3" value="30" spread="2.5"/>
                    <measurement group_id="O4" value="31" spread="3"/>
                    <measurement group_id="O5" value="46" spread="2"/>
                    <measurement group_id="O6" value="26" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&quot;Marijuana High&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" spread="1"/>
                    <measurement group_id="O2" value="10.5" spread="0.5"/>
                    <measurement group_id="O3" value="10" spread="1"/>
                    <measurement group_id="O4" value="11" spread="1.5"/>
                    <measurement group_id="O5" value="16" spread="1.5"/>
                    <measurement group_id="O6" value="10" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&quot;Marijuana Stimulation&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" spread="2"/>
                    <measurement group_id="O2" value="20" spread="2"/>
                    <measurement group_id="O3" value="16" spread="2"/>
                    <measurement group_id="O4" value="20" spread="1.5"/>
                    <measurement group_id="O5" value="30" spread="2"/>
                    <measurement group_id="O6" value="22" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&quot;Want Marijuana&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" spread="1.5"/>
                    <measurement group_id="O2" value="48" spread="1"/>
                    <measurement group_id="O3" value="37" spread="1.5"/>
                    <measurement group_id="O4" value="49" spread="1"/>
                    <measurement group_id="O5" value="45" spread="1.5"/>
                    <measurement group_id="O6" value="50" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 weeks for each treatment and 1 week after receiving last treatment.</time_frame>
      <desc>Safety population included all participants who received at least one intervention. Research staff routinely asked participants to report any adverse events occurring during study sessions and during outpatient washout periods.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo Naltrexone + Inactive Marijuana (0.0% THC)</title>
          <description>0mg naltrexone + 0.0% THC marijuana</description>
        </group>
        <group group_id="E2">
          <title>Placebo Naltrexone + Active Marijuana (5.5% THC)</title>
          <description>0mg naltrexone + 5.5% THC marijuana</description>
        </group>
        <group group_id="E3">
          <title>Placebo Naltrexone + Active Marijuana (6.2% THC)</title>
          <description>0mg naltrexone + 6.2% THC marijuana</description>
        </group>
        <group group_id="E4">
          <title>Naltrexone + Inactive Marijuana (0.0% THC)</title>
          <description>12mg naltrexone + 0.0% THC marijuana</description>
        </group>
        <group group_id="E5">
          <title>Naltrexone + Active Marijuana (5.5% THC)</title>
          <description>12mg naltrexone + 5.5% THC marijuana</description>
        </group>
        <group group_id="E6">
          <title>Naltrexone + Active Marijuana (6.2% THC)</title>
          <description>12mg naltrexone + 6.2% THC marijuana</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study is limited by its small sample size, and portion of males to females.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Margaret Haney, PhD</name_or_title>
      <organization>New York State Psychiatric Institute</organization>
      <phone>646-774-6153</phone>
      <email>mh235@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

